Product Information
EPANED 1 MG/ML ORAL SOLUTION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $4.4785 per ML under NDC 52652400101. Its NADAC has been published 494 times since Apr 19, 2017.
FDA first approved this application on Sep 20, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the enalapril maleate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/mL
Manufacturer
Azurity Pharmaceuticals Inc.NDC
52652400101
Classification
Brand
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ENALAPRIL MALEATEApproval Type
New Drug (NDA)
FDA Application
NDA208686FDA Approved
9/20/2016
TE Code
AB
On Market Since
10/3/2016
Pharmacological Classes
Price Statistics
The NADAC for EPANED 1 MG/ML ORAL SOLUTION has been published 494 times since Apr 19, 2017, and over the history we have for it it has risen 42.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.4785 per ML |
|---|---|
| All-time high | $4.4791 (Aug 12, 2026) |
| All-time low | $3.1305 (Feb 21, 2018) |
| 52-week high | $4.4791 |
| 52-week low | $4.3227 |
| Median price | $3.4336 |
| Average price | $3.6172 |
| Largest weekly change | +9.9% (Jan 4, 2023) |
| Weeks tracked | 494 |
| Tracking since | Apr 19, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the enalapril maleate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
enalapril maleate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EPANED 1 MG/ML ORAL SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for EPANED 1 MG/ML ORAL SOLUTION, manufactured by Azurity Pharmaceuticals Inc., is $4.4785 per ML (NDC 52652400101), effective Sep 30, 2026.
How has the price of EPANED 1 MG/ML ORAL SOLUTION changed over time?
Over the history we have for it, the NADAC for EPANED 1 MG/ML ORAL SOLUTION has risen 42.8%. It has been tracked across 494 weekly CMS publications since Apr 19, 2017.
What are the highest and lowest recorded NADAC prices for EPANED 1 MG/ML ORAL SOLUTION?
Since Apr 19, 2017, the NADAC for EPANED 1 MG/ML ORAL SOLUTION has ranged from a low of $3.1305 (Feb 21, 2018) to a high of $4.4791 (Aug 12, 2026), with a median of $3.4336 per ML.
Are there cheaper alternatives to EPANED 1 MG/ML ORAL SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of EPANED 1 MG/ML ORAL SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EPANED 1 MG/ML ORAL SOLUTION?
EPANED 1 MG/ML ORAL SOLUTION (NDC 52652400101) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.